ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2529

IgG4-Related Disease Paravertebral and Ureteropelvic Mass Presentations are Linked to Specific Disease Features

Federica Bonaso1, Grace McMahon2, Isha Jha2, Guy Katz2, Zachary Wallace3, John Stone4 and Cory Perugino5, 1University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Newton, MA, 4Massachusetts General Hospital , Harvard Medical School, Concord, MA, 5Massachusetts General Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2025

Keywords: IgG4 Related Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease characterized by mass-forming fibrotic lesions. The aim of this work was to characterize the overall clinical and serological findings of paravertebral (PV) and ureteropelvic junction (UPJ) involvement as two uncommon manifestations that are nevertheless regarded as strongly suggestive of IgG4-RD.

Methods: Patients with IgG4-RD were recruited from the Massachusetts General Hospital (MGH) Rheumatology Unit from 2008 to 2025. All patients included fulfilled the 2019 ACR/EULAR Classification Criteria for IgG4-RD. The presence of a PV or UPJ mass was determined by chart and imaging review. Demographics, age at diagnosis, organ involvement, and laboratory values were extracted from the medical record. Patients with PV or UPJ masses were compared to all other IgG4-RD patients in the registry.

Results: Among the 400 patients who fulfilled classification criteria in the MGH IgG4-RD registry, 7 (2%) had a PV mass and 11 (3%) had a UPJ mass. No patient had masses in both the PV and UPJ regions. PV masses were typically located anterolateral to the thoracic spine, abutting the vertebral bodies, and forming a band-like structure (Figure 1A). UPJ masses were typically extrinsic to the kidney and abutting the renal vasculature and ureter but generally not causing hydronephrosis (82%, only two patients presented with hydronephrosis one of whom with concomitant retroperitoneal fibrosis) (Figure 1B). All 7 patients with PV masses and 10 of 11 with UPJ masses were male. In contrast, the percentage of patients in the remainder of the cohort who were male was 68% (261 of 382). The median age of diagnosis for patients with PV masses, UPJ masses, and the IgG4-RD comparison group were 65.1, 65.4 and 61.8 years, respectively. Compared to all other IgG4-RD patients, those with PV masses had significantly higher median serum IgG4 values (891 vs 159 mg/dL, p=0.011) and median absolute and relative eosinophil counts (530 vs 180 cells/uL, p=0.015; 5.7 vs 2.7, p=0.015) (Table 1). IgG4-RD patients with PV masses were more likely to have lacrimal gland (71% vs 31%, p=0.036), submandibular gland (86% vs 41%, p=0.023), retroperitoneal (57% vs 17%, p=0.020), and lung involvement (57% vs 21%, p=0.042). In contrast, patients with UPJ masses were more likely to have prostate (40% vs 11%, p=0.02) and pericardial (18% vs 2%, p=0.028) involvement (Table 2).

Conclusion: Although masses in the PV and UPJ regions are considered highly suggestive of IgG4-RD, they occur in only a small minority of cases. Patients with either PV or UPJ masses tend overwhelmingly to be male, and those with PV masses have more exuberant immunologic disease activity (higher serum IgG4, more frequent peripheral eosinophilia) and more extensive organ involvement (higher frequency of lacrimal gland, submandibular gland, retroperitoneal, and lung involvement) compared to all other patients with IgG4-RD. In contrast, IgG4-RD patients presenting with UPJ masses are more likely to have prostate and pericardial involvement. Further studies incorporating imaging, histopathology, and treatment response among larger cohorts of IgG4-RD are needed to characterize these specific disease features further.

Supporting image 1Table 1. Demographics and Laboratory Values for patients with paravertebral (PV) mass, ureteropelvic junction (UPJ) involvement, and remainder of the IgG4-RD cohort. P-values were calculated by comparing the UPJ and PV groups with the remainder of the cohort by applying Mann-Whitney U test for continuous variables, and Fisher’s exact test for categorical variables. Statistically significant p-values (p < 0.05) are shown in bold.

Supporting image 2Table 2. Organ Involvement distribution across the three groups. P-values were calculated by comparing the UPJ and PV groups with the remainder of the cohort by applying Fisher’s exact test. Statistically significant p-values (p < 0.05) are shown in bold.

Supporting image 3Figure 1. PV mass (A) and UPJ mass (B) imaging from two subjects of our cohort.

(A) Computed tomography (CT) scan showing 4.3 x 1.7 cm soft tissue mass spanning the visceral and paravertebral mediastinum at the T6-T8 level (orange arrow), from left to right axial and sagittal sections. (B) CT scan showing 2.6 cm ill-defined parapelvic soft tissue mass within the left kidney (yellow arrow).


Disclosures: F. Bonaso: None; G. McMahon: None; I. Jha: None; G. Katz: Acepodia, 1, Amgen, 1, 2, 5, Sana, 5, Sanofi, 5, Zenas, 5; Z. Wallace: Amgen, 3; J. Stone: Acepodia, 2, Amgen, 1, 2, argenx, 2, Bristol-Myers Squibb, 2, Novartis, 2, Q32 Bio, 2, Sanofi, 2, Zenas, 2; C. Perugino: Acepodia, 2, Amgen, 1, 2, Bristol-Myers Squibb, 2, Sanofi, 2, Zenas Biopharma, 2.

To cite this abstract in AMA style:

Bonaso F, McMahon G, Jha I, Katz G, Wallace Z, Stone J, Perugino C. IgG4-Related Disease Paravertebral and Ureteropelvic Mass Presentations are Linked to Specific Disease Features [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/igg4-related-disease-paravertebral-and-ureteropelvic-mass-presentations-are-linked-to-specific-disease-features/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/igg4-related-disease-paravertebral-and-ureteropelvic-mass-presentations-are-linked-to-specific-disease-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology